Research Analysts Set Expectations for CMPX FY2027 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Analysts at HC Wainwright dropped their FY2027 earnings estimates for shares of Compass Therapeutics in a report issued on Wednesday, September 23rd. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.57) for the year, down from their previous forecast of ($0.56). The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Compass Therapeutics’ FY2028 earnings at ($0.60) EPS.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02).

A number of other brokerages also recently commented on CMPX. Wedbush set a $4.00 price objective on Compass Therapeutics in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Compass Therapeutics in a research note on Wednesday. Stifel Nicolaus set a $6.00 price objective on shares of Compass Therapeutics in a research note on Monday, June 1st. Wall Street Zen lowered shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, Guggenheim dropped their price target on shares of Compass Therapeutics to $4.00 and set a “buy” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.21.

Compass Therapeutics Stock Down 3.0%

CMPX stock opened at $1.14 on Friday. Compass Therapeutics has a twelve month low of $1.10 and a twelve month high of $6.88. The company has a market cap of $204.40 million, a PE ratio of -2.84 and a beta of 0.95. The business’s 50-day simple moving average is $2.10 and its 200 day simple moving average is $2.90.

Institutional Investors Weigh In On Compass Therapeutics

Several large investors have recently made changes to their positions in CMPX. BlackRock Inc. acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth about $24,707,000. BVF Inc. IL boosted its position in Compass Therapeutics by 63.5% in the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after buying an additional 3,014,842 shares in the last quarter. Palo Alto Investors LP bought a new stake in Compass Therapeutics during the second quarter worth about $12,771,670. Sofinnova Investments Inc. grew its stake in Compass Therapeutics by 65.9% during the fourth quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company’s stock worth $18,072,000 after buying an additional 1,336,560 shares during the last quarter. Finally, NEXTBio Capital Management LP acquired a new stake in shares of Compass Therapeutics during the fourth quarter worth approximately $5,982,000. Institutional investors own 68.43% of the company’s stock.

Key Stories Impacting Compass Therapeutics

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Citizens JMP maintained a “Market Outperform” rating while lowering its price target to $4.00, implying substantial potential upside if Compass can address the FDA’s requirements and advance tovecimig. Citizens JMP price target report
• Neutral Sentiment: A market-data update reported zero shares sold short as of September 24, producing a 0.0-day short-interest ratio. The figure may indicate limited measurable short-selling pressure, although the reported “large increase” in short interest conflicts with the zero-share total and should be treated cautiously.
• Negative Sentiment: The FDA recommended a new tovecimig trial in biliary tract cancer rather than allowing the previously contemplated filing strategy to proceed. The setback could require additional time and funding before a potential application. FDA recommends new Tovecimig trial
• Negative Sentiment: Wall Street analysts viewed the filing strategy as risky after the FDA feedback. Wedbush downgraded CMPX from “Outperform” to “Neutral” and slashed its price target from $5 to $1, while LifeSci Capital also downgraded the stock to “Hold.” These actions reinforce concerns about regulatory risk and reduced near-term catalysts. Wedbush downgrade and price target cut
• Negative Sentiment: The FDA decision erased significant market value and prompted concerns that Compass’s opportunity window is narrowing. Investors now face a longer development path, greater cash-burn risk and uncertainty over whether tovecimig can ultimately reach approval. FDA setback and market reaction

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.